Jim Cramer praises Regeneron Pharmaceuticals, Inc. stock performance, mentioning its CEO’s success. Stock market data indicates an upward trajectory for Regeneron. The company sells medicines for various conditions. Cramer highlights Regeneron’s growth over two decades. While Regeneron shows potential, other AI stocks may offer greater upside. Look for undervalued AI stocks with significant potential.

Read more at Yahoo Finance: Jim Cramer Says He “Should Have Been Recommending Regeneron”